<?xml version='1.0' encoding='UTF-8'?>
<search_results><query id="7050">spotvps review</query><engine status="OK" timestamp="2014-04-20 10:17:17" name="PubMed" id="FW14-e017"/><snippets><snippet id="FW14-e017-7050-01"><link cache="FW14-topics-docs/e017/7050_01.html" timestamp="2014-04-20 10:17:18">http://www.ncbi.nlm.nih.gov/pubmed/24741741</link><title>Ocriplasmin (Jetrea) (125 mcg Intravitreal Injection): For the Treatment of Symptomatic Vitreomacular Adhesion [Internet].</title><description>Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Jan.</description></snippet><snippet id="FW14-e017-7050-02"><link cache="FW14-topics-docs/e017/7050_02.html" timestamp="2014-04-20 10:18:29">http://www.ncbi.nlm.nih.gov/pubmed/24741740</link><title>Somatropin (Genotropin) for Subcutaneous Injection: The Treatment of Short Stature Associated with Turner Syndrome in Patients Whose Epiphyses are not Closed [Internet].</title><description>Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Jan.</description></snippet><snippet id="FW14-e017-7050-03"><link cache="FW14-topics-docs/e017/7050_03.html" timestamp="2014-04-20 10:19:39">http://www.ncbi.nlm.nih.gov/pubmed/24741739</link><title>Somatropin (Genotropin) for Subcutaneous Injection: Long-term Treatment of Children who have Growth Failure Due to an Inadequate Secretion of Endogenous Growth Hormone [Internet].</title><description>Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Jan.</description></snippet><snippet id="FW14-e017-7050-04"><link cache="FW14-topics-docs/e017/7050_04.html" timestamp="2014-04-20 10:23:03">http://www.ncbi.nlm.nih.gov/pubmed/24741737</link><title>Lurasidone Hydrochloride (Latuda): Management of Manifestations of Schizophrenia [Internet].</title><description>Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Jan.</description></snippet><snippet id="FW14-e017-7050-05"><link cache="FW14-topics-docs/e017/7050_05.html" timestamp="2014-04-20 10:23:50">http://www.ncbi.nlm.nih.gov/pubmed/24741736</link><title>Ingenol Mebutate (Picato): Topical Treatment of Non-hyperkeratotic, Non-hypertrophic Actinic Keratosis in Adults [Internet].</title><description>Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Feb.</description></snippet><snippet id="FW14-e017-7050-06"><link cache="FW14-topics-docs/e017/7050_06.html" timestamp="2014-04-20 10:28:03">http://www.ncbi.nlm.nih.gov/pubmed/24741735</link><title>Saxagliptin (Onglyza): Indicated in Patients with Type 2 Diabetes Mellitus to Improve Glycemic Control in Combination with Metformin and a Sulfonylurea when Dual Therapy with these Two Agents, with Diet and Exercise, does not Provide Adequate Glycemic Control [Internet].</title><description>Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2013 Nov.</description></snippet><snippet id="FW14-e017-7050-07"><link cache="FW14-topics-docs/e017/7050_07.html" timestamp="2014-04-20 10:28:54">http://www.ncbi.nlm.nih.gov/pubmed/24741734</link><title>Ulipristal Acetate (Fibristal) (5 mg Tablets): Treatment of Moderate to Severe Signs and Symptoms of Uterine Fibroids in Adult Women of Reproductive Age Who are Eligible for Surgery. The Duration of Treatment is Limited to Three Months [Internet].</title><description>Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2013 Dec.</description></snippet><snippet id="FW14-e017-7050-08"><link cache="FW14-topics-docs/e017/7050_08.html" timestamp="2014-04-20 10:32:36">http://www.ncbi.nlm.nih.gov/pubmed/24741733</link><title>Oncotype DX in Women and Men with ER-Positive HER2-Negative Early Stage Breast Cancer Who are Lymph Node-Positive: A Review of Clinical Effectiveness and Guidelines [Internet].</title><description>Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Jan 24.</description></snippet><snippet id="FW14-e017-7050-09"><link cache="FW14-topics-docs/e017/7050_09.html" timestamp="2014-04-20 10:37:12">http://www.ncbi.nlm.nih.gov/pubmed/24741732</link><title>Positron Emission Tomography in Neurology and Cardiology: A Review of Guidelines and Recommendations [Internet].</title><description>Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Jan 27.</description></snippet><snippet id="FW14-e017-7050-10"><link cache="FW14-topics-docs/e017/7050_10.html" timestamp="2014-04-20 10:38:55">http://www.ncbi.nlm.nih.gov/pubmed/24741731</link><title>Montelukast for Sleep Apnea: A Review of the Clinical Effectiveness, Cost Effectiveness, and Guidelines [Internet].</title><description>Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Jan 17.</description></snippet></snippets></search_results>